Hi Courtney,
I am sorry to hear your dad has progressed to acute stage CML (blast crisis). It is rare when effective treatment starts in Chronic phase, but it can and does happen. It may be that he was in a more advanced stage at diagnosis but that this was not clear from the tests his treating hospital would have done. Nevertheless, he is where he is and will need more treatment intervention than most of us.
It is likely that dasatinib will affect his blood counts quite dramatically- this is because his blood/marrow is populated with more blast (abnormal) cells than normal because the disease is more aggressive at this (blastic) stage. Dasatinib has been used to treat blast stage CML and has shown to be effective in some cases; at least to control the disease while other treatment options are explored. I assume he is in hospital being monitored if his cells are as low as you say- the key here is his platelet count as anything under 20 is quite dangerous as even just a small knock can cause serious bleeding. You did not indicate if his platelets are dangerously low - so let's hope that they at least are above 50.
I think his doctors will be looking to get him back to 2nd chronic phase with dasatinib treatment at this higher dose (140mg) ... so they can then look for a donor- if his siblings do not match then a search on the registries will be necessary. Unrelated donor matched SCT's are pretty much as good as matched donor SCT these days. There is also a chance of double cord blood as a source of stem cells- although I am not sure which transplant centres in the UK would perform this.
It may well be that dasatinib will get him back to chronic phase as long as he can stay on the drug without his blood cells staying too low. His marrow will need some time to manufacture 'normal' blood cells so staying on the drug for as long as possible is key to this.
There are c/trials for CML in blast stage but you would need to do some research ... from a brief skim of www.clinicaltrails.gov I have only found one that is recruiting and that is outside the UK at MDACC in Houston Texas and is a phase 1 trial which is to determine the safe level of dose and assess the safety and tolerability of DS 3032b in subjects with refractory or relapsed AML or ALL, CML in blast phase, or high risk MDS..
https://clinicaltrials.gov/ct2/show/record/NCT02319369?term=chronic+myel...
Where is he being treated? I do hope things improve for him regarding his low blood counts which will enable him to stay on dasatinb.... I would have thought it best to reduce the dose rather than stop altogether given he is blast phase.
Please let us know here how everything goes.
Sandy